Read more about Decoded: Who can get antibody cocktail for Covid-19 and how it works on Business Standard. Used to treat only mild to moderate disease in high-risk Covid-19 patients, doctors feel the treatment can bolster the fight against severe disease
India’s Central Drugs Standards Control Organisation cleared the use of the antibody cocktail for use in emergency situations for treatment of COVID-19, here’s a quick lowdown on how it can help patients
Image used for representational purpose only
BENGALURU: At least eight Covid-19 patients in the city have received a monoclonal antibody cocktail called Casirivimab and Imdevimab. The new drug, which comes in the form of two doses of Rs 60,000 each, offers hope to comorbid patients who have mild to moderate coronavirus infection but face higher risk of developing complications.
Of the eight, two got the drug at St John’s Medical College Hospital on Tuesday. The two men, aged 52 and 38, had undergone a kidney transplant earlier, and have been given the dose to prevent their mild symptoms from turning into a severe infection.
Monoclonal antibody cocktail therapy beneficial in high-risk patients: Experts dtnext.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dtnext.in Daily Mail and Mail on Sunday newspapers.
, May 30 (IANS) The antibody cocktail therapy was administered to a 72-year-old Covid positive patient who is a diabetic with chronic kidney disease, at the Fortis Hospital here on Sunday.Administered one dose of the cocktail intravenously, .